Implications of HER2 amplification in small, node-negative breast cancers: Do asians differ?

World Journal of Surgery

Volumn 36, Issue 2, 2012, Pages 287-294

  Wong, Fuh Yong ^a   Yip, Connie Siew Poh ^a   Chua, Eu Tiong ^a  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HER2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; TRASTUZUMAB;

ADULT; AGED; ARTICLE; ASIAN; BREAST TUMOR; CAUCASIAN; CHINA; ETHNOLOGY; FEMALE; FOLLOW UP; HUMAN; INDIA; KAPLAN MEIER METHOD; MALAYSIA; METABOLISM; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; PROGNOSIS; SINGAPORE; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BREAST NEOPLASMS; CHINA; COMBINED MODALITY THERAPY; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDIA; KAPLAN-MEIER ESTIMATE; MALAYSIA; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RECEPTOR, ERBB-2; SINGAPORE; SURVIVAL RATE;

EID: 84857433476     PISSN: 03642313     EISSN: 14322323     Source Type: Journal    
DOI: 10.1007/s00268-011-1353-7     Document Type: Review

References (24)

1. MJ Piccart-Gebhart M Procter B Leyland-Jones, et al. 2005 Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 1659 1672 16236737 10.1056/NEJMoa052306 1:CAS:528:DC%2BD2MXhtFansr3L (Pubitemid 41464705)
2. EH Romond EA Perez J Bryant, et al. 2005 Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 1673 1684 16236738 10.1056/NEJMoa052122 1:CAS:528:DC%2BD2MXhtFansr3F (Pubitemid 41464706)
3. I Smith M Procter RD Gelber, et al. 2007 2-Year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial Lancet 369 29 36 17208639 10.1016/S0140-6736(07)60028-2 1:CAS:528:DC%2BD2sXit12itg%3D%3D (Pubitemid 46039831)
4. H Joensuu P Bono V Kataja, et al. 2009 Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial J Clin Oncol 27 5685 5692 19884557 10.1200/JCO.2008.21.4577 1:CAS:528:DC%2BC3cXhtVWisb8%3D
5. CA Quiet DJ Ferguson RR Weichselbaum, et al. 1995 Natural history of node-negative breast cancer: a study of 826 patients with long-term follow-up J Clin Oncol 13 1144 1151 7738620 1:STN:280:DyaK2M3ls12gtw%3D%3D
6. G Curigliano G Viale V Bagnardi, et al. 2009 Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer J Clin Oncol 27 5693 5699 19884553 10.1200/JCO.2009.22.0962
7. AM Gonzalez-Angulo JK Litton KR Broglio, et al. 2009 High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller J Clin Oncol 27 5700 5706 19884543 10.1200/JCO.2009.23.2025
8. SP Leong ZZ Shen TJ Liu, et al. 2010 Is breast cancer the same disease in Asian and Western countries? World J Surg 34 2308 2324 10.1007/s00268-010-0683- 1 20607258 10.1007/s00268-010-0683-1
9. M Toi Y Ohashi A Seow, et al. 2010 The Breast Cancer Working Group presentation was divided into three sections: the epidemiology, pathology and treatment of breast cancer Jpn J Clin Oncol 40 Suppl 1 i13 i18 20870914 10.1093/jjco/hyq122
10. Anonymous (2009) TNM Classification of Malignant Tumours. Wiley-Blackwell, Hoboken
11. S Selvarajan BH Bay A Choo, et al. 2002 Effect of fixation period on HER2/neu gene amplification detected by fluorescence in situ hybridization in invasive breast carcinoma J Histochem Cytochem 50 1693 1696 12486093 10.1177/002215540205001215 1:CAS:528:DC%2BD3sXkvVCmsQ%3D%3D (Pubitemid 36078136)
12. V Panet-Raymond PT Truong RE McDonald, et al. 2011 True recurrence versus new primary: an analysis of ipsilateral breast tumor recurrences after breast-conserving therapy Int J Radiat Oncol Biol Phys 81 409 417 21288654 10.1016/j.ijrobp.2010.05.063
13. E Huang TA Buchholz F Meric, et al. 2002 Classifying local disease recurrences after breast conservation therapy based on location and histology: new primary tumors have more favorable outcomes than true local disease recurrences Cancer 95 2059 2067 12412158 10.1002/cncr.10952 (Pubitemid 35253366)
14. RL Bowen J Stebbing LJ Jones 2006 A review of the ethnic differences in breast cancer Pharmacogenomics 7 935 942 16981851 10.2217/14622416.7.6.935 1:CAS:528:DC%2BD28XpvVCksrk%3D (Pubitemid 44446740)
15. GJ Morris S Naidu AK Topham, et al. 2007 Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database Cancer 110 876 884 17620276 10.1002/cncr.22836 (Pubitemid 47257667)
16. ML Telli ET Chang AW Kurian, et al. 2011 Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry Breast Cancer Res Treat 127 471 478 20957431 10.1007/s10549-010-1173-8
17. CA Parise KR Bauer MM Brown, et al. 2009 Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004 Breast J 15 593 602 19764994 10.1111/j.1524-4741.2009.00822.x
18. S Chia B Norris C Speers, et al. 2008 Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers J Clin Oncol 26 5697 5704 19001334 10.1200/JCO.2007.15.8659 1:CAS:528:DC%2BD1MXotFemsw%3D%3D
19. YH Park ST Kim EY Cho, et al. 2010 A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (< or =1 cm) invasive breast cancer: who might be possible candidates for adjuvant treatment? Breast Cancer Res Treat 119 653 661 19957028 10.1007/s10549-009-0665-x
20. MD Althuis JM Dozier WF Anderson, et al. 2005 Global trends in breast cancer incidence and mortality 1973-1997 Int J Epidemiol 34 405 412 15737977 10.1093/ije/dyh414 (Pubitemid 40645331)
21. MJ Rodrigues J Wassermann L Albiges, et al. 2010 Trastuzumab treatment in t1ab, node-negative, human epidermal growth factor receptor 2-overexpressing breast carcinomas J Clin Oncol 28 e541 e542 20660834 10.1200/JCO.2010.29.7952
22. SP Leitner AS Swern D Weinberger, et al. 1995 Predictors of recurrence for patients with small (one centimeter or less) localized breast cancer (T1a, b N0 M0) Cancer 76 2266 2274 8635031 10.1002/1097-0142(19951201)76:11<2266:: AID-CNCR2820761114>3.0.CO;2-T 1:STN:280:DyaK283itlarsg%3D%3D
23. GB Mann ER Port C Rizza, et al. 1999 Six-year follow-up of patients with microinvasive, T1a, and T1b breast carcinoma Ann Surg Oncol 6 591 598 10493629 10.1007/s10434-999-0591-5 1:STN:280:DyaK1MvitFeksA%3D%3D (Pubitemid 29428800)
24. E Bria C Nistico F Cuppone, et al. 2006 Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients Cancer 106 2337 2344 16649217 10.1002/cncr.21886 1:CAS:528:DC%2BD28Xls1Srur0%3D (Pubitemid 43787656)